Head of Pfizer booed by Trump supporters
Pfizer, Haemophilia B and The Nikkei
Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...
Prolific NYC real estate investor David Werner has finally completed the complex real estate puzzle underpinning his planned ...
All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...
Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...
Pfizer is doubling down on its fight against cancer with a 60-second ad set to air during the first quarter of the game.
Mylan, which has an established presence in the central nervous system therapy segment, is expected to leverage its network ...
Pfizer has announced that it has entered into a marketing and supply agreement with Mylan Pharmaceuticals for the marketing and sale of two of its brands, Ativan and Pacitane.
Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.
Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback